Results 201 to 210 of about 259,973 (292)

PD-L1 Status Unknown [PDF]

, 2020
openaire   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Studying Macromolecular Composition in Cell–Cell Interfaces Using 3D Membrane Reconstitution Systems

Advanced Science, EarlyView.
A comprehensive understanding of the interactions between proteins, lipids and glycocalyx components at the immune synapse is still lacking. Here, an artificial and a semi‐artificial model contact system were established to reconstitute the cell‐cell contact in 3D. The model systems enable the examination of macromolecule enrichment or depletion at the
Franziska Ragaller, Amelie Maribel Schneider, Ellen Sjule, Renhua Sun, Xiao Han, Luca Andronico, Edward Jenkins, Michael Dustin, Adnane Achour, Erdinc Sezgin   +9 more
wiley   +1 more source

Efficient Method for High-Throughput Screening of Compound Libraries Targeting Human PD-L1. [PDF]

ACS Omega
Zamani MR, Čermáková K, Hadzima M, Šácha P, Konvalinka J.   +4 more
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Interest of PD-L1 in the management of triple negative breast cancers in Ivorian patients. [PDF]

BMC Womens Health
Diallo A, Aman NA, Traore B, Coulibaly ZI, Kouacou BFA, Nzi MR, Doukoure B, Diomande MI.   +7 more
europepmc   +1 more source

EEPD1 Inhibition Unleashes Antitumor Immunity in Colorectal Cancer by Activating the cGAS‐STING Pathway

Advanced Science, EarlyView.
In colorectal cancer, high expression of the DNA repair protein EEPD1 correlates with immune exclusion and poor prognosis. This study demonstrates that EEPD1 depletion induces genomic instability, leading to cytosolic DNA accumulation and subsequent activation of the cGAS‐STING‐type I interferon pathway. This cascade remodels the tumor microenvironment
Liyun Huo, Chong Wu, Xiaobo Li, Caina Ma, Jiamin Huang, Zishuo Chen, Weiling He, Tianyu Tao, Weijing Zhang   +8 more
wiley   +1 more source

PD-L1-Binding Antigen Presenters: Redirecting Vaccine-Induced Antibodies for Cancer Immunotherapy. [PDF]

Adv Sci (Weinh)
Gao H, Lu L, Xiong X, Li Y, Hu D, Zhang D, Feng Z, Liu C, Liu N, Li X, Tan J, Liu T, Peng L, Lu L, Feng H, Zhong Y, Tan G, Zhang Z, Huang L, Su C, Xue Y, Song S, Fan W, Wang W, Zou F.   +24 more
europepmc   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer. [PDF]

PLoS One
Chen J, Li B, Gan Y, Li P.
europepmc   +1 more source